Rockwell Medical, Inc. (NASDAQ:RMTI) Short Interest Update

Key Points

• Rockwell Medical reported a significant 482.5% increase in short interest, rising from 175,100 shares to 1,020,000 shares by the end of August.
• The company's stock price rose 2.4% on the last trading day and is currently priced at $1.69, with a 1-year trading range from $0.78 to $5.15.
• Analysts have an average rating of "Buy" for Rockwell Medical, with a target price of $4.00 per share, following an upgrade from "sell" to "hold" by Wall Street Zen.

Rockwell Medical, Inc. (NASDAQ:RMTI - Get Free Report) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 1,020,000 shares, an increase of 482.5% from the August 15th total of 175,100 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.9 days. Approximately 3.5% of the shares of the company are sold short. Approximately 3.5% of the shares of the company are sold short. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.9 days.

Rockwell Medical Stock Performance

Shares of NASDAQ RMTI traded down $0.06 during midday trading on Wednesday, reaching $1.63. 688,525 shares of the company were exchanged, compared to its average volume of 599,403. The stock has a market cap of $55.95 million, a P/E ratio of -26.92 and a beta of 1.83. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $5.15. The stock has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.16. The company has a current ratio of 2.89, a quick ratio of 2.51 and a debt-to-equity ratio of 0.30.

Rockwell Medical (NASDAQ:RMTI - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). Rockwell Medical had a negative return on equity of 6.79% and a negative net margin of 2.38%.The firm had revenue of $16.07 million for the quarter, compared to the consensus estimate of $16.33 million. Rockwell Medical has set its FY 2025 guidance at EPS. On average, research analysts forecast that Rockwell Medical will post 0.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Rockwell Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $4.00.

Institutional Investors Weigh In On Rockwell Medical

Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP purchased a new position in Rockwell Medical in the fourth quarter valued at approximately $146,000. Panagora Asset Management Inc. acquired a new stake in shares of Rockwell Medical in the second quarter worth $41,000. Barclays PLC raised its stake in shares of Rockwell Medical by 27.5% in the 4th quarter. Barclays PLC now owns 28,854 shares of the company's stock valued at $59,000 after acquiring an additional 6,229 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Rockwell Medical during the 4th quarter valued at $28,000. 23.31% of the stock is owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.